Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential
Open Access
- 1 August 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (8), 3086-3092
- https://doi.org/10.1128/aac.48.8.3086-3092.2004
Abstract
Doripenem is a broad-spectrum parenteral carbapenem under clinical development in Japan and North America. Its activities against (i) Pseudomonas aeruginosa isolates with graded levels of intrinsic efflux-type resistance, (ii) mutants with various combinations of AmpC and OprD expression, (iii) PU21 transconjugants with class A and D β-lactamases, and (iv) P. aeruginosa isolates with metallo-β-lactamases were tested by the agar dilution method of the National Committee for Clinical Laboratory Standards. Selection of resistant P. aeruginosa mutants was investigated in single- and multistep procedures. Doripenem MICs for isolates without acquired resistance mostly were 0.12 to 0.5 μg/ml, whereas meropenem MICs were 0.25 to 0.5 μg/ml and imipenem MICs were 1 to 2 μg/ml. The MICs of doripenem, meropenem, ertapenem, and noncarbapenems for isolates with increased efflux-type resistance were elevated, whereas the MICs of imipenem were less affected. The MICs of doripenem were increased by the loss of OprD but not by derepression of AmpC; nevertheless, and as with other carbapenems, the impermeability-determined resistance caused by the loss of OprD corequired AmpC activity and was lost in OprD − mutants also lacking AmpC. The TEM, PSE, PER, and OXA enzymes did not significantly protect P. aeruginosa PU21 against the activity of doripenem, whereas MICs of ≥16 μg/ml were seen for clinical isolates with VIM and IMP metallo-β-lactamases. Resistant mutants seemed to be harder to select with doripenem than with other carbapenems (or noncarbapenems), and the fold increases in the MICs were smaller for the resistant mutants. Single-step doripenem mutants were mostly resistant only to carbapenems and had lost OprD; multistep mutants had broader resistance, implying the presence of additional mechanisms, putatively including up-regulated efflux. Most mutants selected with aminoglycosides and quinolones had little or no cross-resistance to carbapenems, including doripenem.Keywords
This publication has 22 references indexed in Scilit:
- Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?Clinical Infectious Diseases, 2002
- The impact of carbapenemases on antimicrobial development and therapy.2002
- Of Pseudomonas, porins, pumps and carbapenemsJournal of Antimicrobial Chemotherapy, 2001
- Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2000
- Emergence of Antibiotic-Resistant Pseudomonas aeruginosa : Comparison of Risks Associated with Different Antipseudomonal AgentsAntimicrobial Agents and Chemotherapy, 1999
- Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 1999
- Carbapenem Activities against Pseudomonas aeruginosa : Respective Contributions of OprD and Efflux SystemsAntimicrobial Agents and Chemotherapy, 1999
- OXA-16, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, from Two Pseudomonas aeruginosa IsolatesAntimicrobial Agents and Chemotherapy, 1998
- Antibiotic Resistance Caused by Gram‐Negative Multidrug Efflux PumpsClinical Infectious Diseases, 1998
- In Vitro and In Vivo Antibacterial Activities of S-4661, a New CarbapenemAntimicrobial Agents and Chemotherapy, 1998